senior notes offering

Hologic intends to use the proceeds of the offering and available cash to refinance its existing 4.375 percent senior unsecured notes due in 2025.

The company said that dried blood-spot sampling improves access to HIV diagnostic testing and care, particularly among HIV-infected people living in remote areas.

The company plans to use the funds for general corporate purposes, including, together with cash on hand, to repay borrowings under its term loan facility. 

The company said that it expects to use the funds for general corporate purposes including the repayment of existing senior notes due 2021.

The firm anticipates using the proceeds for working capital and general corporate purposes, and to pay the net cost of convertible-note hedge transactions.

The company said it intends to use the proceeds for general corporate purposes and to repay borrowings under its term loan facility.

The notes will be sold at an initial effective conversion price of about $38.79 per share, approximately a 30 percent premium to Monday's $29.84 per share closing price.

The company is withdrawing its previous financial guidance for 2020, saying that it cannot predict the extent or duration of the impact of the COVID-19 pandemic.

Thermo Fisher plans to use the proceeds to pay in part for the acquisition of Qiagen, expected to close in the first half of 2021, and for general corporate purposes.

The funds will go toward general corporate purposes, possibly including repayment of a portion of its outstanding commercial paper borrowings.